Agile therapeutics pipeline. Oct 8, 2021 · PRINCETON, N.
Agile therapeutics pipeline Jun 26, 2024 · PRINCETON, N. Feb 19, 2021 · Live Conference Call and Webcast at 4:30 p. Feb 1, 2023 · Agile Therapeutics, Inc. The Company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol, as well as progestin-only birth control patch. AGILE University of Liverpool, a UK government supported platform trial (MRC and Wellcome Trust funding), will sponsor and perform a study in high-risk COVID patients evaluating ALG-097558 as monotherapy or in combination with remdesivir Feb 1, 2023 · Agile Therapeutics, Inc. 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Implicit in this philosophy is the importance of sound corporate governance. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018, it met with the U. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the Company's investigational non-daily, low dose combination hormonal contraceptive patch, Twirla (AG200-15). (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 Agile Therapeutics is located at: 500 College Road East, Suite 310 Princeton, NJ 08540. 19, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m 2 and women with BMI 25-30 kg/m 2 will be presented at the American Feb 27, 2023 · PRINCETON, N. Provide assistance to the Compensation Committee in setting any pipeline or development performance metric(s) under the Company’s incentive compensation programs and reviewing the performance results. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. About AGRX. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline. Of these, 1 products are in the late stages of development and products are in the early development stage. Apr 30, 2021 · PRINCETON, N. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch, AG200-15 (Twirla®). Jan 20, 2022 · About Vigeo Therapeutics Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. Yet, despite the availability of a wide range of birth control options, many women struggle to determine which method is the best fit for them. Click on CLINICAL AND PRE-CLINICAL PIPELINE below to have an overview of our activities or select an individual program. 0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that it intends to offer and sell $30 million of shares of its common stock, subject to market and other conditions, in an underwritten public The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. 85 per one share of common stock and one-half of a About Agile Therapeutics, Inc. , Dec. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA Agile Therapeutics | 3,600 followers on LinkedIn. (Nasdaq:AGRX), a women’s healthcare company, today announced that the U. Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Altomari served as Agile's Executive Chairman from 2004 to 2010. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. Feb 14, 2020 · Twirla ® is a new non-daily, non-invasive contraceptive approved in the U. Read Less Key Principal: Al Altomari See more contacts Twirla ® is a weekly hormonal birth control patch for women with a body mass index (BMI) less than 30 kg/m 2 who can become pregnant. Feb 1, 2023 · Agile Therapeutics (Nasdaq: AGRX) announces FDA approval for extended milestones in the Twirla® long-term safety study, using electronic health records and insurance claims for VTE and ATE risk comparison. 76 a share on revenues of $1. Using an allosteric modulator platform and drug discovery and development expertise, we established a pipeline of clinical and preclinical programs. Regularly review the Company’s pipeline of product candidates and clinical development performance. Wainwright 22nd Annual Global Investment Virtual Conference on Wednesday, September 16, 2020 at 11:30 a. Torrente more than 30 years of experience in the pharmaceutical industry, and is currently a Director at Hyman, Phelps & McNamara PC, a law firm focused on advising clients on FDA matters, where she has practiced since 1998. Dec 22, 2017 · PRINCETON, N. Oct 4, 2023 · About Agile Therapeutics, Inc. Dr. The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. Feb 22, 2024 · PRINCETON, N. . , Oct. PRINCETON, N. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive patch. S. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. New Phase III Data Show Agile Therapeutics’ Low-Dose Patch is Comparable to Combination Oral Contraceptive in a Comparator Study May 7, 2012 747647. Currently, all our product candidates are on hold. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0. 50% of the stock of Agile Therapeutics is held by insiders. , (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the U. Agile Therapeutics | 3,889 followers on LinkedIn. EDT. , March 30, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. The proprietary patch design consists of 5 distinct layers and is less than 1 mm thin. Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women. Agile’s weekly contraceptive patch, Twirla (AG200-15), contains the active ingredients levonorgestrel (LNG) and ethinyl estradiol (EE), both of which are used in many currently marketed contraceptives. Ms. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Agile continues focusing on Twirla's commercialization while evaluating the AG200-15 Extended Regimen Dec 11, 2018 · PRINCETON, N. com. Mar 31, 2022 · Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the JMP Securities Life Sciences Conference 2015 scheduled on Tuesday, June . Our pipeline includes both combined hormonal contraception (CHC) and progestin-only transdermal contraceptive products. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended September 30, 2021 and provided a corporate update. 6. The Board of Directors of Agile Therapeutics (the "Company") sets high standards for the Company's employees, officers and directors. Women’s National Team. Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. com Live Conference Call and Webcast at 4:30 p. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. Nov 2, 2021 · PRINCETON, N. Mar 14, 2022 · PRINCETON, N. (AGRX) stock. New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program Jul 12, 2022 · About Agile Therapeutics, Inc. , June 15, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. 31, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U. commercial launch of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive Jul 23, 2015 · PRINCETON, N. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without 19 hours ago · In July 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has announced results from the GBM-AGILE phase II/III study, which assessed paxalisib in comparison to the standard of care (SOC) for patients with glioblastoma, a severe form of brain cancer with a critical need for new treatments. , a public specialty pharmaceutical company, where she oversaw the launch of its flagship brand XYOSTED, as well as the commercialization of products, strategic planning of developmental assets, as well as new M&A opportunities. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics | 3,897 followers on LinkedIn. Jun 26, 2023 · About Agile Therapeutics, Inc. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. 21, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. 09, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Twirla ® and our pipeline products are based on our Nov 14, 2021 · Agile Therapeutics, Inc. , Feb. Agile Therapeutics ® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. 4 days ago · In the past three months, Agile Therapeutics insiders have not sold or bought any company stock. At our core, we’re guided by a deep respect for science and a passion to change patients’ lives for the better. The trial Aug 26, 2024 · About Agile Therapeutics, Inc. 9 KB Jun 19, 2024 · Agile Therapeutics collects “personal information” as defined by the CCPA, which is information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular consumer or household. All our product and product candidates use Skinfusion ®. Twirla is less effective in women with a BMI of 25 kg/m 2 or more to less than 30 kg/m 2 and should not be used in women whose BMI is 30 kg/m 2 or more. Twirla ® and our pipeline products are based on our Oct 29, 2013 · The three new officers are David Geltzer ’77, founder and director of the Geltzer Family Foundation, chair; Al Altomari ’82, president and CEO of Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021) PRINCETON, N. , March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , vice chair; and Maria Mascioli Charlton MBA ’82, chief financial officer of The Edmar Abrasive Company, also vice chair. Jun 26, 2024 · The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. Once we start getting some good PR in a few months as Twirla hits the market I only see this as going up. For General and Media Inquiries: Email: info@agiletherapeutics. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update. ET PRINCETON, N. , April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today reported financial results for the three and six months ended June 30, 2014, and provided a Company update on activities related to its lead product Sep 13, 2022 · The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. H. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Agile Therapeutics | 3948 seguidores en LinkedIn. Mar 25, 2024 · Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Welsh served for 3 years as the Vice President of Marketing at Antares Pharma Inc. Previously Mr. Aug 17, 2020 · About Agile Therapeutics, Inc. , July 23, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Dec 1, 2022 · PRINCETON, N. Apr 10, 2023 · About Agile Therapeutics, Inc. Oct 8, 2021 · PRINCETON, N. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. For Business Development: Email: bd@agiletherapeutics. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion ® Technology. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Jul 13, 2022 · Agile Therapeutics posted a GAAP loss of $3. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Building on our core capabilities, we are advancing a robust pipeline focused on rare diseases. Only 10. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the 15 th Annual Needham Healthcare Conference on April 13, 2016 at 4:20 The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. Percentage Held by Institutions. , (NASDAQ:AGRX), a women's healthcare company, today announced that the U. agile therapeutics pipeline Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. Investor Relations; Press Releases; Agile Therapeutics Raises $40 Million in a Series C Financing. (Nasdaq: AGRX), a women's healthcare company, today provided an update on Twirla for 2022 and its commercial plan for 2023. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics | 3,829 followers on LinkedIn. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that it has entered into a definitive stock purchase agreement with a group of institutional accredited investors, including both existing Agile Therapeutics to Present at Elsevier Business Intelligence's Therapeutic Area Partnerships. January 19, 2012 . Jun 26, 2024 · AboutAgileTherapeutics,Inc. 2022 Twirla Factory Sales In my humble opinion I think now is a good entry point at $2. 3 KB Aug 7, 2023 · Agile Therapeutics and its subsidiaries are currently working on the development of 3 products that fall under the Drug Delivery Devices, Reproductive Health Devices markets. Mar 19, 2014 · Agile’s Pipeline. Agile Therapeutics is a New Jersey-based, women’s healthcare company that IPO’d in 2014. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2020 financial results after the market close on Monday, March 1, 2021. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , Sept. The company provided these metrics around sales Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Insud's U Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Throughout her impressive career, some of Carli’s accomplishments include being a two-time Olympic gold medalist, two-time FIFA Women’s World Cup champion, a two-time FIFA Player of the Year and the second-ever soccer player to score a hat-trick in any senior FIFA World Cup Final. FDA Agrees to Extended Milestones for Long-Term Twirla ® Safety Study. Feb 1, 2023 · PRINCETON, N. Agile Therapeutics said on Wednesday that the Spain-based pharmaceutical group Insud Pharma is set to acquire the women's healthcare company, valuing AGRX at an enterprise value of ~$45M. Agile Therapeutics discovers a Through the aquisition, Agile Therapeutics will combine with Insud Pharma and focus on the commercialization of Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system contraceptive. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. About Agile Therapeutics, Inc. ET. , June 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Sep 7, 2021 · PRINCETON, N. Aug 17, 2020 · PRINCETON, N. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without PRINCETON, N. Hubbard has served as a member of our Board of Directors since November 2014. Jan 9, 2023 · PRINCETON, N. Agile Therapeutics May 12, 2022 · About Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today reported financial results for the fourth quarter and year ended December 31, 2014. We’re committed to bringing women more contraceptive choices that can keep pace with their wants and needs. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Jun 24, 2019 · Meeting Scheduled for October 30, 2019. Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Twirla ® is a weekly hormonal birth control patch for women with a body mass index (BMI) less than 30 kg/m 2 who can become pregnant. 5. Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B Agile Therapeutics, Inc. Agile’s product and pipeline products are designed to provide women with contraceptive options that safely provide freedom from taking a daily pill. November 29, 2012 . (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics | 3,813 (na) tagasubaybay sa LinkedIn. (Nasdaq: AGRX), a women's healthcare company, today provided an update on the Twirla ® post-marketing studies and status of its ongoing evaluation of the Company’s pipeline. Mar 21, 2023 · Live Conference Call and Webcast at 4:30 p. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance under Nasdaq All current Agile Therapeutics product and product candidates utilize Skinfusion ® technology. Jul 12, 2022 · Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. “We are encouraged by solid double-digit growth in prescription demand as measured by cycles dispensed. Oct 31, 2023 · SAN DIEGO, Oct. Twirla is in Phase 3 clinical development and Agile anticipates receiving data from their Phase 3 trial by the end of 2015. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Food and Drug Administration’s (“FDA”) Division of Bone, Reproductive, and Urologic Products (“DBRUP”) to discuss the design of a comparative wear Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Jan 26, 2023 · PRINCETON, N. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced that it has entered into a definitive merger PRINCETON, N. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0. Agile Therapeutics, Inc. Food and Drug Administration (FDA) has approved Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system. (Nasdaq: AGRX), a women’s healthcare company, today announced the U. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2019 on Tuesday January 8, 2019 at 10:00 AM Pacific Time. 7. , a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Other products in Agile's pipeline are also contraceptives but with different hormone configurations. Interim safety data is due by November 2029, with the final report in November 2035. Patent and Trademark Office issued Notices of Allowance between July 21 and 23 for four patent applications with claims directed to The Investor Relations website contains information about Agile Therapeutics's business for stockholders, potential investors, and financial analysts. J. C. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. In addition to Twirla, Agile is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to May 23, 2014 · Agile Therapeutics, Inc. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options. The firm is focused on designing contraceptive options that offer freedom from the traditional choice Prior to joining Agile, Ms. , Jan. Percentage Held by Insiders. 14, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) resubmission for Twirla ® (AG200-15), an investigational Dr. Jan 16, 2015 · PRINCETON, New Jersey, Jan. Agile Therapeutics is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. , March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. pdf 490. 54. (Nasdaq: AGRX), a women’s healthcare company, today announced that a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee of the U. , March 26, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. NOVEL PATCH DESIGN KEEPS ACTIVE INGREDIENTS IN PLACE Sep 2, 2020 · Agile Therapeutics Vice President of Marketing Amy Welsh added, “We believe that finding the right contraceptive method is an important factor in sexual and reproductive health. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Aegle Therapeutics Corporation (Aegle) is developing a first-in-class therapy using extracellular vesicles secreted by allogeneic bone marrow derived mesenchymal stem cells to treat rare diseases, including dystrophic epidermolysis bullosa, a rare pediatric blistering disease. 747630. , Aug. , June 24, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. The company is building a first-in-class drug development pipeline being led by VT1021, its dual-modulating compound that blocks the CD47 immune checkpoint and reprograms CD36 mediated activities. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , May 22, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. m. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Product Pipeline; Investors. Feb 1, 2023 · As part of Twirla’s approval, the United States Food and Drug Administration (FDA) required the Company to conduct a long-term prospective, multi-center clinical post-marketing requirement study Mar 28, 2024 · Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update Mar 25, 2024 · Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. , March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Altomari served as President and Chief Executive Officer from 2010 to 2016. 02, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H. Founded in 1997, Agile Therapeutics has operation in Princeton, New Jersey. 76 million. 20, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. 747609. , a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. Dec 12, 2023 · About Agile Therapeutics, Inc. Twirla ® and our pipeline products are based on our May 15, 2024 · Agile Therapeutics will not host a conference call and webcast relating to its First Quarter 2024 financial results and does not plan to do so moving forward. Food and Drug Administration Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results March 12, 2018 PRINCETON, N. Torrente has served as a member of our Board since October 2021. 92% of the stock of Agile Therapeutics is held by institutions. , Nov. FDA Previously Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019. , expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Aug 26, 2024 · A high-level overview of Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the market close on Wednesday, March 22, 2023. Hubbard currently serves on the Strategic Advisory Board of Genstar Capital and is responsible for advising the private equity firm on investments in the area of healthcare. Aug 26, 2024 · Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc. Dec 7, 2020 · Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE). Only 0. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics | 3,869 followers on LinkedIn. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. Twirla® and our pipeline products are based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Mar 31, 2022 · Newly retired, Carli Lloyd is a former professional soccer player for the U. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the market close on Wednesday, March May 16, 2019 · FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019. pdf 400. pdf 401. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Agile Therapeutics | 3,895 followers on LinkedIn. Eastern Time Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Both top and bottom line numbers beat the limited consensus. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without Mar 31, 2022 · Agile Therapeutics, Inc. hucbbr lfal eyvh zhwa sbww syh fpzu dvl mqine dpd